There have been no clinical trials on the effects of cannabis or CBD oil in people living with dementia.
There is also a large amount of variation in the levels of THC and CBD oil in different strains of the plant so the effects could depend on the type of cannabis used.
Is there any evidence behind the cannabis and CBD oil claims?
There are no research studies that prove cannabis, or products such as cannabis oil (CBD oil), can stop, slow, reverse or prevent the diseases that cause dementia.
Cannabis is made up for two main components – Tetrahydrocannabinol and Cannabidiol.
But more research is needed to understand the long-term effects of taking cannabis, and whether it is an effective and safe way to tackle dementia symptoms.
Brad Wyatt, CEO of CBD Global Sciences, shared, “I always knew that science would be an integral for the approval and deployment of CBD and other cannabinoids for global use as a treatment for a multitude of ailments. We are seeing this happen on many different fronts, further proving the need for the all-natural remedy for the human body. I believe that we will discover through research and clinical trials that the basic compounds found in the cannabis plant will continue to fill a plethora of deficiencies that the human body needs.”
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
March 25, 2021 07:30 ET | Source: CBD Global Sciences Inc. CBD Global Sciences Inc.
Their study finds a two-week treatment course in mice boosted the proteins TREM2 and IL-33, both of which contribute to the brain’s immune cells being able to clean out dead cells and other debris in the body. When plaques pile up in the brain, they start interfering with the communication between neurons and lead to brain cell death. Levels of both proteins decrease in patients with Alzheimer’s.
Denver, Colorado, March 25, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — CBD Global Sciences, Inc. (OTC: CBDNF) (CSE: CBDN) (Frankfurt:GS3), (“CBD Global” or the “Company”), is pleased to share that a recent study has revealed that CBD may be key to stopping triggers for Alzheimer’s disease, according to researchers from the Medical College of Georgia in Augusta University.
Methods: Eleven AD patients were recruited to an open label, 4 weeks, prospective trial.
Conclusion: Adding MCO to AD patients’ pharmacotherapy is safe and a promising treatment option.
Background: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer’s disease (AD).
Objective: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD).
Results: Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p < 0.01) and NPI score were recorded (44.4 to 12.8; p < 0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress.